Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy.
Veraprapas KittipibulMuthiah VaduganathanUchechukwu IkeabaKaren ChiswellJaved ButlerAdam D DeVorePaul A HeidenreichJoanna C HuangMichelle M KittlesonKaren E Joynt MaddoxKarthik K LinganathanJames J McDermottAnjali Tiku OwensPamela N PetersonScott D SolomonOrly VardenyClyde W YancyGregg C FonarowStephen J GreenePublished in: JACC. Heart failure (2024)
In this large cohort of older U.S. adults hospitalized for HF, cause-specific costs of care differed among patients with EF ≤40% vs >40%. SGLT2i significantly reduced the rate of HF and all-cause hospitalizations irrespective of EF in clinical trials, and implementation of SGLT2i therapy in clinical practice is projected to reduce costs by $1,439 to $2,668 per patient over the 1 year post-discharge, excluding drug costs.
Keyphrases
- healthcare
- heart failure
- clinical trial
- clinical practice
- acute heart failure
- primary care
- case report
- stem cells
- emergency department
- pain management
- left ventricular
- community dwelling
- atrial fibrillation
- middle aged
- affordable care act
- bone marrow
- chronic pain
- open label
- adverse drug
- electronic health record
- double blind